Drug design strategies for the treatment of prostate cancer

Expert Opinion on Drug Discovery

Volumn 10, Issue 1, 2015, Pages 81-90

  Lauer, Richard C ^a   Friend, Sarah C ^a   Rietz, Cecilia ^b   Pasqualini, Renata ^b   Arap, Wadih ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen deprivation therapy; Chemotherapy; Drug design; Immunotherapy; Prostate cancer; Radionuclides; Vascular targeting

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; CABOZANTINIB; DENOSUMAB; ENZALUTAMIDE; LIGAND; SIPULEUCEL T; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG DESIGN; GENE EXPRESSION; GENE FUSION; HUMAN; IMMUNOTHERAPY; NON CASTRATION RESISTANT METASTATIC PROSTATE CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTOSTERONE SYNTHESIS; VASCULAR TUMOR; MALE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DESIGN; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84918777626     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.978855     Document Type: Review

References (76)

1. CDC, Centers for Disease Control and Prevention. Available from: www.cdc. gov/cancer/dcpc/data/men.htm
2. The American Cancer Society. What are the key statistics about prostate cancer? 2014.Available from: www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics
3. Leland WK, Chung Isaacs WB, et al. Prostate cancer biology, genetics, and the new therapeutics. 2nd edition. Humana Press; New Jersey: 2007
4. NCI Surveilliance, epidemiology and end results program. Available from: http://seer.cancer.gov/statfacts/html/prost.html
5. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer II The effects of castration on advanced carcinoma of the prostate gland. Arch Surg-Chicago 1941;43(2):209-23
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9
8. Harris JL, Richards RS, Chow CWK, et al. BMCC1 is an AP-2 associated endosomal protein in prostate cancer cells. PLoS One 2013;8(9):e73880
9. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28(4):251-65
10. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90
11. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59(11):2511-15
12. Palmberg C, Koivisto P, Kakkola L, et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000;164(6):1992-5
13. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009;31(Pt 2):2312-31
14. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8
15. Smith M, Klotz L, van der Meulen E, et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analyses of prospective clinical trials of degarelix. J Urol 2011;186(5):1835-42
16. Buchanan G, Greenberg NM, Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7(5):1273-81
17. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92(23):1918-25
18. Yeh S, Lin HK, Kang HY, et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Nat Acad Sci USA 1999;96(10):5458-63
19. Agus DB, Scher HI, Higgins B, et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res 1999;59(19):4761-4
20. Zhou H, Li XM, Meinkoth J, et al. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000;151(3):483-94
21. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95(1):29-39
22. Medema RH, Kops GJ, Bos JL, et al. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404(6779):782-7
23. Wu X, Senechal K, Neshat MS, et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Nat Acad Sci USA 1998;95(26):15587-91
24. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143(2):390-400
25. Liu AY, Corey E, Bladou F, et al. Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65(1):85-9
26. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-4
27. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26(2):263-73
28. Tso CL, McBride WH, Sun J, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer journal 2000;6(4):220-33
29. Chung LW, Baseman A, Assikis V, et al. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005;173(1):10-20d
30. Wang Y, Revelo MP, Sudilovsky D, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64:149-59
31. Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014;74(4):p1272-83
32. Lucas J, Heinlein C, Kim T, et al. The androgen-regulated protease. TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Disc 2014. [Epub ahead of print]
33. Tannok I. "Is there evidence that chemotherapy is of benefit in patients with carcinoma of the prostate?". J Clin Oncol 1985;3(7):1013-21
34. Trump DL, Havlin KH, Messing EM, et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1989;7(8):1093-8
35. Tannok IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Candadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64
36. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
37. Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metatstatic castrate-resistant prostate cancer (mCRPC) in the TAX327 trial. J. of Geriatric Oncol 2014;5(2):119-26
38. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27(15):2450-6
39. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
40. Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 2012;6:13-18
41. de Bono JS, Logothedis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:21
42. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014.Available from: http://dx.doi.org/10.1016/j.eururo.2014.02.056
43. Beer TM, Armstrong AJ, Rathkopf Y, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
44. Merseburger AS, Scher HI, Bellmunt J, et al. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int 2014. [Epub ahead of print]
45. Shirley M, McCormack PL. Radium-223 Dichloride: a review of its use in patients with castrate-resistant prostate cancer with symptomatic bone metastases. Drugs 2014;74:579-86
46. Prommer E. Palliative oncology: denosumab. Am J Hosp Palliat Care 2014. [Epub ahead of print] Available from: http://ajh.sagepub.com/content/early/2014/06/12/1049909114539035
47. Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triade OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15(6):457-75
48. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
49. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55
50. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastatis, angiogenesis and tumor growth. Mol Cancer Ther 2011;10:2298-308
51. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontuniation trial. J Clin Oncol 2013;31:412-19
52. Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014;26(3):259-64
53. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12(3):245-55
54. Prolaris® post prostatectomy technical specifications myriad genetic laboratories, Inc. Updated: July 1, 2013. Available from: http://www.prolaris.com/information-for-physicians/pathology/technical-specifications/
55. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8
56. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
57. Peshwa MV, Shi JD, Ruegg C, et al. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36(2):129-38
58. Ma Y, Shurin GV, Gutkin DW, et al. Tumor associated regulatory dendritic cells. Semin Cancer Biol 2012;22(4):298-306
59. Snellhammer PF, Chodak G, Whitmore JBm, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81(6): 1297-302
60. Huber ML, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104(4):273-9
61. DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006;4:1
62. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6(5):1632-8
63. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(7):1099-105
64. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Nat Acad Sci USA 1997;94(15):8099-103
65. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
66. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24(7):1813-21
67. Kwon E, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:700-12
68. Parker C. A near miss for prostate cancer immunotherapy. Comment. Lancet Oncol 2014;15:669
69. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Nat Acad Sci USA 2002;99(19):12293-7
70. Sfanos KS, Bruno TC, Meeker AK, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009;69(15):1694-703
71. Zurita AJ, Troncoso P, Cardo-Vila M, et al. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 2004;64:435-9
72. Cardo-Vila M, Zurita AJ, Giordano R, et al. A ligand peptide motif selected from a human cancer patient is a receptor-interacting site with human interleukin-11. PLoS One 2008;3(10):e3452
73. Arap MA, Lahdenranta J, Mintz P, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004;6(3):275-84
74. Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004;10:625-32
75. Lewis VO, Ozawa MG, Deavers MT, et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in oseosarcoma: consistent data from cell lines, orthotopic models and human tumor samples. Cancer Res 2009;69:1995-9
76. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 2011;3(108):108ra112